Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,567 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Regimen Clear all
Recruiting Not applicable Interventional

Nutritional Supplementation in Geriatric Hip Fractures

NCT06773000
View directory record Official record
Conditions
Geriatric Hip Fracture
Interventions
XR™ Recovery Supplement, XR Carbohydrate Loading Supplement
Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
65 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 30, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC

NCT05611671
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Colitis, Ulcerative
Interventions
MORF-057, Placebo
Drug
Lead sponsor
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Industry
Eligibility
18 Years to 85 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
8
States / cities
Sun City, Arizona • Lancaster, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 30, 2026, 10:04 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

NCT03970447
View directory record Official record
Conditions
Glioblastoma
Interventions
Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine
Drug · Radiation · Biological
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years and older
Enrollment
2,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
42
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 30, 2026, 10:04 AM EDT
Completed Phase 3 Interventional Results available

A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension

NCT03533114
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
JZP-258, Placebo Oral Solution
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
40
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 30, 2026, 10:04 AM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis

NCT04864392
View directory record Official record
Conditions
Osteoarthritis
Interventions
LNA043, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 75 Years
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
23
States / cities
Phoenix, Arizona • Tucson, Arizona • La Mesa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 30, 2026, 10:04 AM EDT
Completed Not applicable Interventional

Telephone-Based Counseling for Depression in Parkinson's Disease

NCT02505737
View directory record Official record
Conditions
Depression, Parkinson's Disease
Interventions
TH-CBT, Enhanced Usual Care
Behavioral · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
35 Years to 85 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 30, 2026, 10:04 AM EDT
Recruiting Not applicable Interventional

Improving Glycemic Control With Telemedicine and Smart Insulin Pens

NCT06918977
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
InPen Smart insulin pen, traditional/standard insulin pen
Device · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 30, 2026, 10:04 AM EDT
Completed Phase 2Phase 3 Interventional

African American Study of Kidney Disease and Hypertension ABPM Pilot Study

NCT00582777
View directory record Official record
Conditions
Hypertensive Renal Disease
Interventions
USUAL - take your BP Meds as you usually do, HS DOSING, ADD On Dosing
Behavioral · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced Oct 30, 2026, 10:04 AM EDT
Not listed Phase 2 Interventional

Safety and Efficacy Study of an Interactive Wound Dressing (KC002) for the Treatment of Diabetic Foot Ulcers

NCT00330265
View directory record Official record
Conditions
Foot Ulcer, Diabetes
Interventions
KC-002, Conventional Wound Therapy
Device · Other
Lead sponsor
KeraCure
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
21
States / cities
Montgomery, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2008 · Synced Oct 30, 2026, 10:04 AM EDT
Completed Not applicable Interventional

Study of Intensive, Home-Based Family Therapy to Improve Illness Management in Youth With Diabetes

NCT00372814
View directory record Official record
Conditions
Diabetes Mellitus, Insulin Dependent
Interventions
Intensive Home-Based Family Therapy, Supportive Telephone Calls
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
10 Years to 17 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 30, 2026, 10:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Study of Continuous Oral Contraceptives and Doxycycline

NCT00480532
View directory record Official record
Conditions
Contraceptives, Oral
Interventions
Lybrel, Doxycycline, Oracea, Placebo, Doxycycline 100bid x5 days at the time of bleeding, Subantimicrobial doxycycline daily, placebo daily
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
2
States / cities
Honolulu, Hawaii • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Oct 30, 2026, 10:04 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis

NCT00794664
View directory record Official record
Conditions
Hypercholesterolemia, Coronary Heart Disease
Interventions
Mipomersen, Placebo
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Jupiter, Florida • Winter Park, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 30, 2026, 10:04 AM EDT
Terminated Not applicable Interventional

Adhesive Capsulitis and Dynamic Splinting

NCT01874821
View directory record Official record
Conditions
Adhesive Capsulitis
Interventions
Dynasplint, Standard of Care
Device · Other
Lead sponsor
Dynasplint Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Oct 30, 2026, 10:04 AM EDT
Completed Not applicable Interventional Results available

Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles

NCT01231984
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
4 mm x 32G Pen Needle, 8mm x 31G Pen Needle, 12.7mm x 29G Pen Needle
Device
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Escondido, California • Atlanta, Georgia • Springfield, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 30, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.

NCT06244316
View directory record Official record
Conditions
Dry Eye Disease
Interventions
rhNGF 5 μg/mL, rhNGF 10 μg/mL, Vehicle (Placebo solution)
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
10
States / cities
Chandler, Arizona • Torrance, California • Colorado Springs, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 30, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients

NCT01537432
View directory record Official record
Conditions
Psoriasis, Plaque-type Psoriasis
Interventions
secukinumab, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
12
States / cities
Birmingham, Alabama • Pasadena, California • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2016 · Synced Oct 30, 2026, 10:04 AM EDT
Completed Phase 4 Interventional Results available

Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery

NCT00357656
View directory record Official record
Conditions
Hemophilia A
Interventions
Recombinant Protein-Free Factor VIII (rAHF-PFM)
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 70 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
10
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 30, 2026, 10:04 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant

NCT05654922
View directory record Official record
Conditions
Pre-Bronchiolitis Obliterans Syndrome
Interventions
ARINA-1, Standard of care only
Drug · Other
Lead sponsor
Renovion, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 30, 2026, 10:04 AM EDT
Completed Phase 3 Interventional

Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

NCT05742802
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tozorakimab 1, Tozorakimab 2, Placebo
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
1,713 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
46
States / cities
Sheffield, Alabama • Tempe, Arizona • Lincoln, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 30, 2026, 10:04 AM EDT
Withdrawn Phase 2 Interventional

A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors

NCT04791228
View directory record Official record
Conditions
Solid Tumors, Soft Tissue Sarcoma, Ewing Sarcoma, Malignant Epithelial Neoplasm, Rhabdomyosarcoma, Wilms Tumor, Hepatic Tumor, Germ Cell Tumor, Bone Metastases
Interventions
Magnetic Resonance-Guided High Intensity Focused Ultrasound, Lyso-thermosensitive Liposomal Doxorubicin
Device · Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 1, 2025 · Synced Oct 30, 2026, 10:04 AM EDT
Not listed Not applicable Interventional

The Small Intestine Bacterial Overgrowth Study Pilot

NCT03588845
View directory record Official record
Conditions
Systemic Sclerosis, Small Intestinal Bacterial Overgrowth
Interventions
Treatment Protocol, Standard of Care
Other
Lead sponsor
Canadian Scleroderma Research Group
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 30, 2026, 10:04 AM EDT
Terminated Phase 2 Interventional

An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+

NCT01116245
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
ADXS11-001 (Lm-LLO-E7), Placebo Control
Biological · Drug
Lead sponsor
Advaxis, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
15
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Oct 30, 2026, 10:04 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.

NCT05064878
View directory record Official record
Conditions
CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures
Interventions
Fenfluramine, Placebo
Drug
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
1 Year to 35 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 30, 2026, 10:04 AM EDT
Active, not recruiting Phase 3 Interventional

Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma

NCT02659293
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Carfilzomib, Dexamethasone, Lenalidomide (Control)
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 30, 2026, 10:04 AM EDT